BLT2, a leukotriene B-4 receptor 2, as a novel prognostic biomarker of triple-negative breast cancer
- Authors
- Park, Jaein; Jang, Jae-Hyun; Park, Geun-Soo; Chung, Yunro; You, Hye Jin; Kim, Jae-Hong
- Issue Date
- 2018
- Publisher
- KOREAN SOCIETY BIOCHEMISTRY & MOLECULAR BIOLOGY
- Keywords
- BLT2; Leukotriene B4 receptor-2; TNBC; Triple-negative breast cancer
- Citation
- BMB REPORTS, v.51, no.8, pp.373 - 377
- Indexed
- SCIE
SCOPUS
KCI
- Journal Title
- BMB REPORTS
- Volume
- 51
- Number
- 8
- Start Page
- 373
- End Page
- 377
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/81011
- DOI
- 10.5483/BMBRep.2018.51.8.127
- ISSN
- 1976-6696
- Abstract
- Triple-negative breast cancer (TNBC) is considered to be a notorious type of cancer due to its aggressive metastatic potential and poor prognosis. Recent evidence suggests that BLT2, a low-affinity LTB4 receptor is critically associated with the phenotypes of TNBC cells, including invasion, metastasis, and survival. Furthermore, in a group of 545 breast cancer patients with metastasis, we observed that the high-BLT2 subgroup had a lower disease-free-survival rate than the low-BLT2 subgroup. Thus, we theorized that anti-BLT2 strategies could facilitate the development of new therapies used for TNBC. This review focuses on recent discoveries regarding BLT2 and its roles in as a novel prognostic biomarker in TNBC.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Life Sciences and Biotechnology > Division of Life Sciences > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.